

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai HeartCare Medical Technology  
Corporation Limited**

**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 6609)**

**(I) CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR;  
AND  
(II) APPOINTMENT OF CHAIRMAN OF THE SUPERVISORY  
COMMITTEE**

**CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR**

Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) held a meeting of the employee representative on July 25, 2025 and elected Mr. Liu Hongbao (“**Mr. Liu**”) as an employee representative supervisor (the “**Employee Representative Supervisor**”) of the second session of the supervisory committee of the Company (the “**Supervisory Committee**”). The appointment of Mr. Liu as the Employee Representative Supervisor shall take effect from July 25, 2025 and his term of office will be in line with that of the second session of the Supervisory Committee and he shall not receive any remuneration as the Employee Representative Supervisor during the term of his office.

On the same day, Mr. Liu Baiwei tendered his resignation as a supervisor of the Company due to his personal work arrangements and ceased to perform his duties as an Employee Representative Supervisor and the Chairman of the Supervisory Committee, and has confirmed that he has no disagreement with the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company, the Supervisory Committee or the Company, and that there are no other matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and there is no existing or pending litigation or claim by him against the Group. The Company would like to take this opportunity to express its gratitude to Mr. Liu Baiwei for his contributions to the Group during his term of service as a supervisor of the Company.

The biographical details of Mr. Liu are set out below:

Mr. Liu, aged 36, joined the Company in February 2021 as the national sales director. Prior to joining the Company, he served as the sales and marketing manager of the neurointervention department of Genesis MedTech Group from September 2018 to February 2021. Moreover, he served as the regional supervisor of the neurointervention department of Covidien Healthcare Devices International Trading (Shanghai) Co. Ltd. from May 2016 to September 2018; and served as the senior sales representative of Terumo Medical Products (Shanghai) Co., Ltd. from July 2013 to May 2016; prior to that, he served as the medical information communication specialist of Pfizer Investment Co., Ltd. from July 2011 to July 2013. He has extensive experience in sales and marketing of medical devices. Mr. Liu is also a participant under the Company's 2021 H Share Incentive Scheme adopted on November 1, 2021, as of the date of this announcement, Mr. Liu is interested in 40,400 H Shares through such incentive scheme.

Mr. Liu obtained his bachelor of pharmacology from Shandong University of Traditional Chinese Medicine in July 2011 and a master of business administration from Wuhan University in July 2024.

Save as disclosed above, as at the date of this announcement, Mr. Liu confirmed that: (i) he does not related to any directors, supervisors, senior management, substantial shareholders or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company; (ii) he does not hold and has not held any directorships in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) he does not have and has not held other major appointments or professional qualifications; (iv) he does not have or deemed to have any interest in the shares or underlying shares of the Company or associated corporations (as defined in Part XV of the Securities and Futures Ordinance) (Chapter 571 of the Laws of Hong Kong); and (v) he does not hold any other positions in the Company or other members of the Group.

Mr. Liu has also confirmed that, save as disclosed above, there is no other matters that need to be brought to the attention of Shareholders or the Stock Exchange nor any other information required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

## APPOINTMENT OF CHAIRMAN OF THE SUPERVISORY COMMITTEE

The Supervisory Committee is pleased to announce that, following the change of the Employee Representative Supervisor, a Supervisory Committee meeting was held on July 25, 2025. Ms. Jiang Xue (“**Ms. Jiang**”) was appointed as the chairman of the second session of the Supervisory Committee with effect from July 25, 2025 until the expiration of the term of office of the second session of the Supervisory Committee.

Biographical information of Ms. Jiang is set out in the Company’s annual report for the year ended December 31, 2024 which was published on April 23, 2025. Save as disclosed above, as at the date of this announcement, there has been no other change of such information. Save for the information set out above, there is no other information to be disclosed pursuant to the requirements of the provisions under Rule 13.51(2) of the Listing Rules nor is there any other matter that needs to be brought to the attention of the Shareholders in relation to the change of the responsibilities of Ms. Jiang.

By order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**Wang Guohui**  
*Chairman of the Board*

Shanghai, July 25, 2025

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*